Publications

Export 7 results:
Sort by: Author Title Type [ Year (Asc)]
Filters: Author is Mak, Koon-Hou  [Clear All Filters]
2009
Mak K-, Bhatt DL, Shao M, Hankey GJ, Easton DJ, Fox KA, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J. 2009;157(4):658-65. Abstract
Mak K-, Bhatt DL, Shao M, Haffner SM, Hamm CW, Hankey GJ, et al. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J. 2009;30(7):857-65. Abstract
Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak K-, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone [CHARISMA] trial). Am J Cardiol. 2009;103(10):1359-63. Abstract
2011
Weber M, Bhatt DL, Brennan DM, Hankey GJ, Steinhubl SR, Johnston CS, et al. High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart. 2011;97(8):626-31. Abstract
2012
Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European heart journal. 2012. Abstract
Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012;33(17):2143-50. Abstract
Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012;33(17):2143-50. Abstract